rosiglitazone has been researched along with latanoprost in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jiang, XY; Wang, SY; Xiao, O; Yang, PS; Yang, SJ; Yu, K; Zhou, SY | 1 |
3 other study(ies) available for rosiglitazone and latanoprost
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Macular oedema linked to latanoprost and rosiglitazone.
Topics: Antihypertensive Agents; Humans; Hypoglycemic Agents; Latanoprost; Macular Edema; Prostaglandins F, Synthetic; Rosiglitazone; Thiazolidinediones | 2010 |
Effects of PPAR-γ and RXR-α on mouse meibomian gland epithelial cells during inflammation induced by latanoprost.
Topics: Animals; Anti-Inflammatory Agents; Chemokines; Cyclooxygenase 2; Cytokines; Epithelial Cells; Inflammation; Interleukin-6; Keratin-1; Keratin-17; Latanoprost; Matrix Metalloproteinase 9; Meibomian Glands; Mice; Ophthalmic Solutions; PPAR gamma; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Tumor Necrosis Factor-alpha | 2022 |